Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Factorial randomized study of IL-6 and IL-1 blockade versus standard care in severe COVID-19
2020-001500-41Phase 3Completed
- Sponsor
- Ghent University Hospital
- Start
- Apr 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tocilizumab, siltuximab and anakinra in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Ghent University Hospital. Primary endpoint: Time to clinical improvement. Started Apr 2020; status: completed.
02
Drugs
tocilizumabsiltuximabanakinra
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001500-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001500-41.